Immunexpress Appoints Dr. Bea Arnold to Board of Directors
SEATTLE, Sept. 29, 2015 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that Dr. Bea Arnold has joined the Company's Board of Directors.
"We are delighted to welcome Dr. Arnold to our Board of the Directors," said Roslyn Brandon, President and CEO of Immunexpress. "Debiopharm is a Series A and B investor in Immunexpress and a supportive collaborator. Dr. Arnold's experience in diagnostics and business development will be valuable as we advance the SeptiCyte® technology through regulatory clearance and into the market."
Dr. Arnold has been with Debiopharm Group since 2003 and has served as the Associate Director of Debiopharm Diagnostics SA since 2014. Previously she was the Head of New Opportunities, Business Development and Licensing and a Molecular Biology and Biotechnology Manager at Debiopharm International. Prior to joining Debiopharm, she held sales and marketing positions with Gnothis SA and BioRad Laboratories. Dr. Arnold has a Ph.D. in Science from the University of Lausanne, Switzerland.
About Immunexpress
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients with, or at risk of, sepsis. Immunexpress's SeptiCyte® technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response can diagnose sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer platforms. For more information visit www.Immunexpress.com.
Follow Immunexpress on Twitter at twitter.com/Immunexpress and LinkedIn at www.linkedin.com/company/immunexpress-inc.
About Debiopharm Diagnostics
Debiopharm Diagnostics' mission is to invest in innovative diagnostic companies developing platforms and content to complement in-house diagnostic activities, give insight into cutting-edge diagnostics and facilitate access to new technologies. Since 2008, Debiopharm Diagnostics has invested over USD 90 million and led 10 out of the 14 last investment rounds in its portfolio companies.
For more information, please visit: www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4262
[email protected]
[email protected]
Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
[email protected]
Tel: +41 (0)21 321 01 11
SOURCE Immunexpress, Inc.
Share this article